Peter Valent Peter Valent Emir Hadzijusufovic Emir Hadzijusufovic Irina Sadovnik Irina Sadovnik Thomas W. Grunt Thomas W. Grunt Barbara Peter Barbara Peter Michael Willmann Michael Willmann Harald Herrmann Harald Herrmann Daniel Ivanov Daniel Ivanov Gregor Eisenwort Gregor Eisenwort Heidrun Karlic Heidrun Karlic Georg Greiner Georg Greiner Karoline V. Gleixner Karoline V. Gleixner Thomas Rülicke Thomas Rülicke Maik Dahlhoff Maik Dahlhoff Philipp Staber Philipp Staber Wolfgang R. Sperr Wolfgang R. Sperr Michael Pfeilstöcker Michael Pfeilstöcker Thomas Lion Thomas Lion Felix Keil Felix Keil Gregor Hoermann Gregor Hoermann Springer 2024 Cancer stem cells, also known as leukemic stem cells (LSC) in the context of leukemias, are an emerging topic in translational oncology and hematology. The Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO) was established in 2008 with the aim to translate LSC concepts into clinical practice. Major specific aims of the LBI HO are to identify LSC in various blood cell disorders and to improve anti-leukemic therapies by establishing LSC-targeting and LSC-eradicating approaches with the ultimate aim to translate these concepts into clinical practice. In addition, the LBI HO identified a number of diagnostic and prognostic LSC markers in various blood cell malignancies. Members of the LBI HO have also developed precision medicine tools and personalized medicine approaches around LSC in applied hematology. As a result, diagnosis, prognostication and therapy have improved in the past 10 years. Major disease models are myeloid leukemias and mast cell neoplasms. Finally, the LBI HO consortium launched several projects in the field of open innovation in science where patient-derived initiatives and their input supported the scientific community. Key aims for the future of the LBI HO are to develop LSC-related concepts and strategies further, with the long-term vision to cure more patients with hematologic malignancies. PDFDocument eng 2024-12-02T09:45:10.662277Z 2024 Acute Myeloid-Leukemia Cancer Stem-Cells Therapeutic Target Initiating Cells Progenitor Cells Melanoma-Cells Kinase Domain Identification Midostaurin Heterogeneity 341078 b application/pdf application/pdf http://creativecommons.org/licenses/by/4.0/